
    
      PRIMARY OBJECTIVES:

      I. To identify a maximum tolerated dose of bendamustine (bendamustine hydrochloride) in
      patients with multiple myeloma.

      SECONDARY OBJECTIVES:

      I. To evaluate the safety of escalating doses of bendamustine in patients with multiple
      myeloma.

      II. To describe the response after bendamustine

      OUTLINE: This is a dose-escalation study.

      Patients receive bendamustine hydrochloride intravenously (IV) over 60-180 minutes on days 1
      and 2.
    
  